Loss of function Cbl-c mutations in solid tumors.

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Receptor Tyrosine Kinase (RTK) signaling is crucial for cellular functions, and its dysregulation drives cancer.
• Cbl proteins are RING finger ubiquitin ligases that negatively regulate RTKs, with mutations linked to myeloid neoplasias.
• Cbl-c is specifically expressed in epithelial cells and plays a role in RTK regulation.

Purpose of the Study:

• To investigate the role of a novel Cbl-c mutant identified in a mouse mammary cancer model.
• To determine the functional consequences of Cbl-c mutations in solid tumor pathogenesis.
• To explore the potential contribution of Cbl-c dysfunction to human solid tumors.

Main Methods:

• Identification and characterization of a novel Cbl-c mutant cDNA from a transgenic mouse model.
• Genomic analysis to determine mutation origin (somatic vs. germline).
• Cell-based assays (NIH 3T3 transformation, EGFR ubiquitination, and downregulation studies) to assess mutant protein function.
• Data mining of human cancer databases for Cbl-c mutations in solid tumors.

Main Results:

• A novel Cbl-c mutant with a deletion in the RING finger domain was identified in a mouse mammary cancer.
• The mutant Cbl-c enhanced NIH 3T3 cell transformation and exhibited dominant-negative effects on EGFR ubiquitination and downregulation.
• Mechanistically, the mutant Cbl-c binds EGFR, preventing wild-type Cbl recruitment and function.
• Human Cbl-c mutations associated with solid tumors were identified, showing similar loss-of-function and dominant-negative effects.

Conclusions:

• Loss of Cbl-c function, due to mutations like the one identified, can contribute to solid tumor development.
• The mutant Cbl-c acts in a dominant-negative manner, interfering with wild-type Cbl's tumor-suppressive functions.
• Cbl-c dysfunction is a potential mechanism in the pathogenesis of both murine and human solid tumors.